421 related articles for article (PubMed ID: 30348660)
21. Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline.
Chen A; Smith KP; Whitfield BA; Zucchi PC; Lasco TM; Bias TE; Kirby JE; Hirsch EB
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):365-367. PubMed ID: 28535946
[TBL] [Abstract][Full Text] [Related]
22. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
Shields RK; Nguyen MH; Chen L; Press EG; Potoski BA; Marini RV; Doi Y; Kreiswirth BN; Clancy CJ
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559250
[TBL] [Abstract][Full Text] [Related]
23. Mortality impact of empirical antimicrobial therapy in ESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital.
Lim CL; Spelman D
Infect Dis Health; 2019 Aug; 24(3):124-133. PubMed ID: 30928569
[TBL] [Abstract][Full Text] [Related]
24. Assessment of mortality stratified by meropenem minimum inhibitory concentration in patients with Enterobacteriaceae bacteraemia: A patient-level analysis of published data.
O'Donnell JN; Rhodes NJ; Biehle LR; Esterly JS; Patel TS; McLaughlin MM; Hirsch EB
Int J Antimicrob Agents; 2020 Feb; 55(2):105849. PubMed ID: 31770628
[TBL] [Abstract][Full Text] [Related]
25. [The efficacy and safety of different antimicrobial regimens in carbapenem-resistant
Sun WM; Zhou H; Shen LS; Yang Q; Ma WJ; Zhou JY
Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):566-571. PubMed ID: 31365977
[No Abstract] [Full Text] [Related]
26. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.
Gutiérrez-Gutiérrez B; Salamanca E; de Cueto M; Hsueh PR; Viale P; Paño-Pardo JR; Venditti M; Tumbarello M; Daikos G; Cantón R; Doi Y; Tuon FF; Karaiskos I; Pérez-Nadales E; Schwaber MJ; Azap ÖK; Souli M; Roilides E; Pournaras S; Akova M; Pérez F; Bermejo J; Oliver A; Almela M; Lowman W; Almirante B; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J;
Lancet Infect Dis; 2017 Jul; 17(7):726-734. PubMed ID: 28442293
[TBL] [Abstract][Full Text] [Related]
27. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.
Jorgensen SCJ; Rybak MJ
Pharmacotherapy; 2018 Apr; 38(4):444-461. PubMed ID: 29427523
[TBL] [Abstract][Full Text] [Related]
28. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
[TBL] [Abstract][Full Text] [Related]
29. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
Bassetti M; Giacobbe DR; Patel N; Tillotson G; Massey J
Adv Ther; 2019 Jul; 36(7):1771-1777. PubMed ID: 31098989
[TBL] [Abstract][Full Text] [Related]
31. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018.
Perovic O; Ismail H; Quan V; Bamford C; Nana T; Chibabhai V; Bhola P; Ramjathan P; Swe Swe-Han K; Wadula J; Whitelaw A; Smith M; Mbelle N; Singh-Moodley A;
Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1287-1294. PubMed ID: 32124106
[TBL] [Abstract][Full Text] [Related]
32. Factors associated with mortality in Infections caused by Carbapenem-resistant Enterobacteriaceae.
Gualtero S; Valderrama S; Valencia M; Rueda D; Muñoz-Velandia O; Ariza B; Cortes G; Salgado D; Porras Y; Niño A
J Infect Dev Ctries; 2020 Jun; 14(6):654-659. PubMed ID: 32683357
[TBL] [Abstract][Full Text] [Related]
33. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
[TBL] [Abstract][Full Text] [Related]
34. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY
Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555
[TBL] [Abstract][Full Text] [Related]
35. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
Huang SS; Lee MH; Leu HS
J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.
Patel TS; Nagel JL
J Clin Microbiol; 2015 Jan; 53(1):201-5. PubMed ID: 25378572
[TBL] [Abstract][Full Text] [Related]
37. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
[TBL] [Abstract][Full Text] [Related]
38. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.
Qureshi ZA; Paterson DL; Potoski BA; Kilayko MC; Sandovsky G; Sordillo E; Polsky B; Adams-Haduch JM; Doi Y
Antimicrob Agents Chemother; 2012 Apr; 56(4):2108-13. PubMed ID: 22252816
[TBL] [Abstract][Full Text] [Related]
39.
Hagiya H; Aoki K; Akeda Y; Yamamoto N; Shanmugakani RK; Ishii Y; Tomono K
Microb Drug Resist; 2019; 25(6):839-845. PubMed ID: 30835635
[No Abstract] [Full Text] [Related]
40. Bacterial characteristics of carbapenem-resistant Enterobacteriaceae (CRE) colonized strains and their correlation with subsequent infection.
Lin Q; Wang Y; Yu J; Li S; Zhang Y; Wang H; Lai X; Liu D; Mao L; Luo Y; Tang G; Chen Z; Sun Z
BMC Infect Dis; 2021 Jul; 21(1):638. PubMed ID: 34215214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
